The past few years have witnessed remarkable advancements in treatments for conditions once deemed incurable. Notably, the recent approval of lecanemab in the UK marks a significant step forward in the fight against early-stage Alzheimer’s disease. While it does not provide a cure, this medication paves the way for managing dementia as a chronic illness through pharmacological interventions.
Despite the recognition of lecanemab as a transformative therapy, access remains limited. Currently, 55 million individuals worldwide are grappling with dementia, a number projected to surge to 139 million by 2050. This escalating crisis poses a formidable challenge for global healthcare systems and underscores the urgent need for accessible treatment options.
